Integrated use of AI tumor volumetrics and advanced MRI: a novel paradigm

Integrated use of AI tumor volumetrics and advanced MRI: a novel paradigm

Integrated use of AI tumor volumetrics and advanced MRI to assess early response to Temferon™ in a Phase-2 GBM trial: a novel paradigm

IAG, Image Analysis Group, a strategic partner to life-sciences companies developing novel treatments, today announced that an important abstract on the use of Artificial Intellegence (AI) and advanced imaging in oncology was accepted to this year’s American Society Clinical Oncology Virtual Conference, ASCO21.

The below abstracts are based upon the data genenrated by IAG, Image Analysis Group and biotech partner Genenta Science‘s in the latest clinical research studies. These show how advanced imaging and integrated use of AI can aid cancer drug development by assessing response earlier and more accurately.

The accepted abstracts are:

Title:Integrated use of AI tumor volumetrics and advanced MRI to assess early response to Temferon™ in a Phase-2 GBM trial: a novel paradigm.” 
Authors: Sotirios Bisdas, Diana Dupont-Roettger, Valeria Cuccarini, Bernhard Gentner, Marica Eoli , Luigi Naldini, Fabio Ciceri, Gaetano Finocchiaro, Carlo Russo, Maria Grazia Bruzzone.

Title:A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study).
Authors: Gaetano Finocchiaro, Bernhard Gentner, Francesca Farina, Alessia Capotondo, Marica Eoli, Elena Anghileri, Matteo Giovanni Carabba, Valeria Cuccarini, Francesco Di Meco, Federico Legnani, Bianca Pollo, Maria Grazia Bruzzone, Marco Saini, Paolo Ferroli, Roberto Pallini, Alessandro Olivi, Stefania Mazzoleni, Carlo Russo, Luigi Naldini, Fabio Ciceri.

Abstracts will be released by ASCO on May 19, 2021, at 5:00 PM EDT  on

To learn more about IAG’s work in oncology, join our scientific leadership team in a series of LIVE webinars:

Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer

The Role of Central Imaging in Successful Oncology Clinical Trials

Send your questions to

Prof. Sotirios Bisdas is IAG’s Sn Director of Neuro-Oncology Research. He is a consultant neuroradiologist and MRI Lead in the Department of Neuroradiology at the National Hospital for Neurology in London, Senior Lecturer in Neuroradiology at the Institute of Neurology University College London, and Professor of Radiology at Eberhard Karls University in Tübingen, Germany. He has authored over 130 peer-reviewed publications and serves as member of the editorial board of several leading journals in Radiology and Neuroradiology. He is also reviewer for leading journals in Neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

Dr. Diana Dupont-Roettger is Chief Scientific Alliance Officer. She is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.

About IAG:

 IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development.

If you are interested in meeting our expert team at ASCO’21 Virtual Conference please email <>